Cargando…

Self-Reported and Physiologic Reactions to Third BNT162b2 mRNA COVID-19 (Booster) Vaccine Dose

Despite extensive technological advances in recent years, objective and continuous assessment of physiologic measures after vaccination is rarely performed. We conducted a prospective observational study to evaluate short-term self-reported and physiologic reactions to the booster BNT162b2 mRNA (Pfi...

Descripción completa

Detalles Bibliográficos
Autores principales: Mofaz, Merav, Yechezkel, Matan, Guan, Grace, Brandeau, Margaret L., Patalon, Tal, Gazit, Sivan, Yamin, Dan, Shmueli, Erez
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Centers for Disease Control and Prevention 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9239876/
https://www.ncbi.nlm.nih.gov/pubmed/35654410
http://dx.doi.org/10.3201/eid2807.212330
_version_ 1784737408373227520
author Mofaz, Merav
Yechezkel, Matan
Guan, Grace
Brandeau, Margaret L.
Patalon, Tal
Gazit, Sivan
Yamin, Dan
Shmueli, Erez
author_facet Mofaz, Merav
Yechezkel, Matan
Guan, Grace
Brandeau, Margaret L.
Patalon, Tal
Gazit, Sivan
Yamin, Dan
Shmueli, Erez
author_sort Mofaz, Merav
collection PubMed
description Despite extensive technological advances in recent years, objective and continuous assessment of physiologic measures after vaccination is rarely performed. We conducted a prospective observational study to evaluate short-term self-reported and physiologic reactions to the booster BNT162b2 mRNA (Pfizer-BioNTech, https://www.pfizer.com) vaccine dose. A total of 1,609 participants were equipped with smartwatches and completed daily questionnaires through a dedicated mobile application. The extent of systemic reactions reported after the booster dose was similar to that of the second dose and considerably greater than that of the first dose. Analyses of objective heart rate and heart rate variability measures recorded by smartwatches further supported this finding. Subjective and objective reactions after the booster dose were more apparent in younger participants and in participants who did not have underlying medical conditions. Our findings further support the safety of the booster dose from subjective and objective perspectives and underscore the need for integrating wearables in clinical trials.
format Online
Article
Text
id pubmed-9239876
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Centers for Disease Control and Prevention
record_format MEDLINE/PubMed
spelling pubmed-92398762022-07-06 Self-Reported and Physiologic Reactions to Third BNT162b2 mRNA COVID-19 (Booster) Vaccine Dose Mofaz, Merav Yechezkel, Matan Guan, Grace Brandeau, Margaret L. Patalon, Tal Gazit, Sivan Yamin, Dan Shmueli, Erez Emerg Infect Dis Research Despite extensive technological advances in recent years, objective and continuous assessment of physiologic measures after vaccination is rarely performed. We conducted a prospective observational study to evaluate short-term self-reported and physiologic reactions to the booster BNT162b2 mRNA (Pfizer-BioNTech, https://www.pfizer.com) vaccine dose. A total of 1,609 participants were equipped with smartwatches and completed daily questionnaires through a dedicated mobile application. The extent of systemic reactions reported after the booster dose was similar to that of the second dose and considerably greater than that of the first dose. Analyses of objective heart rate and heart rate variability measures recorded by smartwatches further supported this finding. Subjective and objective reactions after the booster dose were more apparent in younger participants and in participants who did not have underlying medical conditions. Our findings further support the safety of the booster dose from subjective and objective perspectives and underscore the need for integrating wearables in clinical trials. Centers for Disease Control and Prevention 2022-07 /pmc/articles/PMC9239876/ /pubmed/35654410 http://dx.doi.org/10.3201/eid2807.212330 Text en https://creativecommons.org/licenses/by/4.0/Emerging Infectious Diseases is a publication of the U.S. Government. This publication is in the public domain and is therefore without copyright. All text from this work may be reprinted freely. Use of these materials should be properly cited.
spellingShingle Research
Mofaz, Merav
Yechezkel, Matan
Guan, Grace
Brandeau, Margaret L.
Patalon, Tal
Gazit, Sivan
Yamin, Dan
Shmueli, Erez
Self-Reported and Physiologic Reactions to Third BNT162b2 mRNA COVID-19 (Booster) Vaccine Dose
title Self-Reported and Physiologic Reactions to Third BNT162b2 mRNA COVID-19 (Booster) Vaccine Dose
title_full Self-Reported and Physiologic Reactions to Third BNT162b2 mRNA COVID-19 (Booster) Vaccine Dose
title_fullStr Self-Reported and Physiologic Reactions to Third BNT162b2 mRNA COVID-19 (Booster) Vaccine Dose
title_full_unstemmed Self-Reported and Physiologic Reactions to Third BNT162b2 mRNA COVID-19 (Booster) Vaccine Dose
title_short Self-Reported and Physiologic Reactions to Third BNT162b2 mRNA COVID-19 (Booster) Vaccine Dose
title_sort self-reported and physiologic reactions to third bnt162b2 mrna covid-19 (booster) vaccine dose
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9239876/
https://www.ncbi.nlm.nih.gov/pubmed/35654410
http://dx.doi.org/10.3201/eid2807.212330
work_keys_str_mv AT mofazmerav selfreportedandphysiologicreactionstothirdbnt162b2mrnacovid19boostervaccinedose
AT yechezkelmatan selfreportedandphysiologicreactionstothirdbnt162b2mrnacovid19boostervaccinedose
AT guangrace selfreportedandphysiologicreactionstothirdbnt162b2mrnacovid19boostervaccinedose
AT brandeaumargaretl selfreportedandphysiologicreactionstothirdbnt162b2mrnacovid19boostervaccinedose
AT patalontal selfreportedandphysiologicreactionstothirdbnt162b2mrnacovid19boostervaccinedose
AT gazitsivan selfreportedandphysiologicreactionstothirdbnt162b2mrnacovid19boostervaccinedose
AT yamindan selfreportedandphysiologicreactionstothirdbnt162b2mrnacovid19boostervaccinedose
AT shmuelierez selfreportedandphysiologicreactionstothirdbnt162b2mrnacovid19boostervaccinedose